Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has taken a big step toward Phase III clinical trial initiation today. The company has submitted a Clinical Trial Application (CTA) for a phase III clinical trial involving their leading program, AWKN-P001, designed for the treatment of Severe Alcohol Use Disorder (SAUD).

Awakn's planned Phase III trial of AWKN-P001 will be an n=280, two-armed randomized placebo-controlled trial, delivered in the UK across ten @NHSuk sites. For more information, visit: $AWKN $AWKNF

— Awakn™ Life Sciences (@awakn_ls) September 6, 2023

AWKN-P00, a novel combined therapeutic consisting of racemic ketamine and delivered via intravenous (IV), represents an innovative treatment approach …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.